Challenges in Growth Hormone Therapy
Published on 8. June 1999
Book
Hardback
320 pages
978-0-632-05164-9 (ISBN)
Description
The whole area of growth hormone has been shrouded in controversy for some years. In the US, anxious parents apply pressure for their little ones to receive this elixir, regarless of whether there is a medical condition to treat. More recently, health care organisations have balked at the very high cost of growth hormone therapy while, with a greater consciousness of evidence-based medicine, there is also growing concerns about its efficay. There are now fears about the safety of long-term growth hormone administration with possible risks of increased cardiovascular disease and diabetes, although the latter seems to be a temporary phenomenon. At the clinical level there are also uncertainties about what optimum dosing schedules to use for both children and adults, and how to manage the transition from childhood to adult (when to stop giving hormone, how to follow up). Questions and Uncertainties about Growth Hormone Therapy will tackle theses issues and provide a timely and controversial review of these topics for endocrinologists and paediatricians.
More details
Language
English
Place of publication
Oxford
United Kingdom
Publishing group
John Wiley and Sons Ltd
Target group
College/higher education
Professional and scholarly
Dimensions
Height: 244 mm
Width: 172 mm
Weight
758 gr
ISBN-13
978-0-632-05164-9 (9780632051649)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Content
1 GH replacement in children - what is the optimum dosing schedule? 2 What is the current status of GH therapy in children with Turner's syndrome? 3 Is there a role for GH therapy in Noonan's syndrome? 4 Does GH therapy influence final height in skeletal dysplasia syndromes? 5 Is there a role for GH therapy in short normal children? 6 What is the role of GH therapy in children born small for gestational age? 7 Is cardiovascular mortality increased in hypopituitary adults? 8 How should we diagnose GH deficiency in hypopituitary adults? 9 What is the impact of GH deficiency on bone density in childhood-onset and adult-onset GH deficiency, and how effective is GH replacement? 10 Individual susceptibility and GH dosing regimen in adults 11 What is the impact of GH deficiency and GH replacement on quality of life in childhood-onset and adult-onset GH deficiency? 12 Is there an upper limit for GH replacement in hypopituitary adults? 13 Is open-ended GH replacement a safe therapy? 14 How should we evaluate GH treated patients at completion of linear growth? 15 How should we transfer patients from paediatric to adult clinics? 16 Is there a role for GH therapy in osteoporosis and in ageing? 17 What is the current status of GH therapy in catabolic adults? 18 Is GH therapy indicated in the metabolic syndrome? 19 Does GH therapy have a role in management of cardiac failure?